The abstract is read at the publisher; the summary is JClub's.
DCST1 is linked to cisplatin resistance in muscle-invasive and metastatic bladder cancer, with DCST1 upregulation predicting poor prognosis and driving PANoptosis suppression.
- Why it matters: Cisplatin resistance limits first-line treatment effectiveness in bladder cancer, and the mechanisms enabling survival under chemotherapy stress remain insufficiently defined.
- What they did: The study combined a systematic CRISPR-Cas9 E3 ligase library screen with GDSC drug-sensitivity data, then tested DCST1 loss in vitro and in vivo and mapped DCST1’s K11/K27-linked ubiquitination of NFAT5 at K450.
- The result: DCST1 deficiency sensitized bladder cancer cells to cisplatin by triggering PANoptosis, while NFAT5 stabilization supported an anti-PANoptotic transcriptional program; digoxin inhibited NFAT5 and overcame DCST1-mediated resistance.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.